These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Lung cancer AND PSA
536 results:

  • 1. 99mTc-PSMA and 99mTc-FAPI-46 Uptake in Pulmonary Lymphangitic Carcinomatosis: A Rare Form of Metastasis in Prostate cancer Patient, Responding to Modified Treatments.
    Raeisi N; Aghaee A; Aryana K; Soltani S; Ghorbani H
    Clin Nucl Med; 2024 Dec; 49(12):e691-e692. PubMed ID: 39485876
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Prostate cancer: A Review of Genetics, Current Biomarkers and Personalised Treatments.
    Wilson TK; Zishiri OT
    Cancer Rep (Hoboken); 2024 Oct; 7(10):e70016. PubMed ID: 39410867
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. A systematic review of Selenium as a complementary treatment in cancer patients.
    Krannich F; Mücke R; Büntzel J; Schomburg L; Micke O; Hübner J; Dörfler J
    Complement Ther Med; 2024 Nov; 86():103095. PubMed ID: 39374898
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Budget impact analysis of pembrolizumab versus the novel PD-1 inhibitor toripalimab in locally advanced or metastatic nonsquamous non-small cell lung cancer.
    Abraham I; Calamia M; Alkhatib N; Pondel M; MacDonald K
    J Med Econ; 2024; 27(sup3):36-50. PubMed ID: 39359042
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Cost-effectiveness analysis of selpercatinib versus chemotherapy and pembrolizumab in the first-line treatment of rearranged during transfection fusion-positive non-small cell lung cancer in the United States.
    Yi H; Cao Y; Shi F; Wei X; Han S
    Int J Clin Pharm; 2024 Dec; 46(6):1427-1435. PubMed ID: 39352419
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. A single-center retrospective review of metastatic prostate cancer on PSMA position emission tomography/computed tomography: Beyond lymph nodes and bones.
    De Jesus GNC; Pereira V; Karak P; Shearier E
    Prostate; 2025 Jan; 85(1):13-20. PubMed ID: 39295117
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China.
    Lang W; Ai Q; He Y; Pan Y; Jiang Q; Ouyang M; Sun T
    Int J Clin Pharm; 2024 Dec; 46(6):1536-1545. PubMed ID: 39276261
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Prostate cancer screening: Is it time for a new approach? A review article.
    Mikulas CJ; Ali K; Onteddu N
    J Investig Med; 2025 Jan; 73(1):27-34. PubMed ID: 39205324
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. [Prostate cancer screening? Only evidence-based, risk-adjusted, and organized!].
    Albers P; Becker N
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2024 Sep; 67(9):1047-1053. PubMed ID: 39102055
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. [Diagnosis and treatment of small-cell carcinoma of the prostate: A report of 2 cases].
    Lu LW; Shi XQ; Xu S; Wu D; Wang L; Fu D; Xu ZY
    Zhonghua Nan Ke Xue; 2024 Jan; 30(1):40-43. PubMed ID: 39046412
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Cost-effectiveness analysis of amivantamab plus chemotherapy for non-small cell lung cancer patients with epidermal growth factor receptor exon 20 insertions in the United States.
    Cao Y; Yi H; Shi F; Wei X; Han S
    Int J Clin Pharm; 2024 Dec; 46(6):1335-1344. PubMed ID: 38990458
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Analysis of the immune-inflammatory indices for patients with metastatic hormone-sensitive and castration-resistant prostate cancer.
    Wang Z; Liu H; Zhu Q; Chen J; Zhao J; Zeng H
    BMC Cancer; 2024 Jul; 24(1):817. PubMed ID: 38978000
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. [A Case of Metastatic Prostate cancer with Neuroendocrine Differentiation with Long-Term Survival after Multidisciplinary Therapy].
    Fujita K; Kato M; Kosugi Y; Sekido Y; Matsui N; Masuda K; Yamamoto S; Matsue T; Iguchi K; Yukimatsu N; Otoshi T; Yamasaki T; Kuratsukuri K; Kohashi K; Uchida J
    Hinyokika Kiyo; 2024 Jun; 70(6):173-177. PubMed ID: 38967030
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Indirect comparison of capmatinib treatment from GEOMETRY mono-1 trial to SOC in German patients with locally advanced or metastatic NSCLC harboring METex14 skipping mutations.
    Kron A; Scheffler M; Wiesweg M; Hummel HD; Kulhavy J; Gatteloehner S; Kollmeier J; Schubart C; Groß T; Demes MC; Keymel S; Joosten M; Merkelbach-Bruse S; Wölwer CB; Tufman A; Kauffmann-Guerrero D; Oeser K; Zehaczek M; Jeratsch U; Wolf J
    Eur J Cancer; 2024 Aug; 207():114158. PubMed ID: 38941869
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Shortness of breath on the day of discharge: an early alert for post-discharge complications in patients undergoing lung cancer surgery.
    Kang D; Lei C; Zhang Y; Wei X; Dai W; Xu W; Zhang J; Yu Q; Su X; Huang Y; Shi Q
    J Cardiothorac Surg; 2024 Jun; 19(1):398. PubMed ID: 38937786
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Randomized trials of psa screening.
    Dave P; Carlsson SV; Watts K
    Urol Oncol; 2025 Jan; 43(1):23-28. PubMed ID: 38926075
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Electronic symptom monitoring after lung cancer surgery: establishing a core set of patient-reported outcomes for surgical oncology care in a longitudinal cohort study.
    Yu H; Lei C; Wei X; Wang Y; Xu W; Tang L; Dai W; Liao J; Pu Y; Gong R; Su X; Yu Q; Zhang J; Zhang L; Huang Y; Zhuang X; Bai J; Wang Z; Li Q; Shi Q
    Int J Surg; 2024 Oct; 110(10):6591-6600. PubMed ID: 38896873
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Undergoing lung Surgery (psa-lung) was appropriate for symptom assessment after discharge.
    Su X; Huang Y; Gong R; Xu W; Dai W; Pu Y; Yu J; Yu Q; Zhang L; Zhang J; Shi Q
    Qual Life Res; 2024 Jul; 33(7):1807-1818. PubMed ID: 38735915
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. The cost-effectiveness of iruplinalkib versus alectinib in anaplastic lymphoma kinase-positive crizotinib-resistant advanced non-small-cell lung cancer patients in China.
    Dai Z; Xu J; Chang F; Zhou W; Ren T; Qiu J; Lu Y; Lu Y
    Front Public Health; 2024; 12():1333487. PubMed ID: 38699428
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Prostate cancer Radioligand Therapy: Beta-labeled Radiopharmaceuticals.
    Yechiel Y; Chicheportiche A; Keidar Z; Ben-Haim S
    PET Clin; 2024 Jul; 19(3):389-399. PubMed ID: 38679550
    [TBL] [Abstract] [Full Text] [Related]  

    [Next]

    of 27.